The aim is to determine if specific Epstein-Barr virus antibodies can reliably differentiate multiple sclerosis from other neuroinflammatory diseases.
Case-control study design
Comparison of antibody levels between multiple sclerosis and other neuroinflammatory conditions
Measurement of EBNA-1 peptide antibody titers
Persistent high-level EBNA-1 antibody titers correlate with multiple sclerosis
Antibody levels effectively differentiate MS from MOGAD and NMOSD
Findings support the potential of EBNA-1 as a biomarker for MS diagnosis
Abstract
Results of this case-control study reveal that persistent high-level EBNA-1 peptide antibody titers may serve as a reliable biomarker for differentiating MS from MOGAD, and NMOSD.
Demander à l'IA
Like
Bookmark
Share
View Full Paper
Demander à l'IA
Like
Bookmark
Share
View Full Paper
Epstein-Barr Virus Antibodies to Differentiate Multiple Sclerosis From Other Neuroinflammatory Diseases | Synapse